Cutting-Edge PET/CT Scanner Is Clinically Operational

Publication
Article
OncologyONCOLOGY Vol 16 No 6
Volume 16
Issue 6

The world’s first clinically operational molecular imager with lutetium oxyorthosilicate (LSO) technology-the biograph LSO, manufactured by Siemens Medical Solutions-has produced a precisely registered, combined positron-emission tomography (PET)/computed tomography (CT) image in 7 minutes at the Hong Kong Baptist Hospital. The biograph LSO imager uses the high-speed properties of LSO as the PET scintillator to provide shorter scan times and unmatched patient throughput.

The world’s first clinicallyoperational molecular imager with lutetium oxyorthosilicate (LSO) technology—thebiograph LSO, manufactured by Siemens Medical Solutions—has produced aprecisely registered, combined positron-emission tomography (PET)/computedtomography (CT) image in 7 minutes at the Hong Kong Baptist Hospital. Thebiograph LSO imager uses the high-speed properties of LSO as the PETscintillator to provide shorter scan times and unmatched patient throughput.

The biograph LSO merges three components—the ECAT ACCEL PETscanner, the SOMATOM Emotion spiral CT scanner, and syngo multimodality software—intoa powerful scanning device that creates a precisely registered molecular imagein 15 minutes or less. The resulting image makes it possible for oncologists andother health-care providers to view detailed anatomy and the biologicalprocesses of internal organs and living tissue at the molecular level in asingle, noninvasive diagnostic procedure.

In addition to the biograph LSO, the biograph is available with bismuthgermanate (BGO) crystal technology—a proven and economic scintillator forquality high-resolution PET imaging. The first commercial installation of thebiograph with BGO technology was completed last fall at Memorial Sloan-KetteringCancer Center in Manhattan.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
5 experts are featured in this series
4 experts in this video
2 experts are featured in this series.
4 experts in this video
4 experts in this video
4 experts in this video
2 experts are featured in this series.
Related Content